In a regional deal, AstraZeneca licensed rights to FibroGen’s renal candidate in an alliance worth $815 million; Elan finally agreed to an $8.3 billion takeover by Perrigo; biopharma financing totaled $7.1 billion and $2 billion in June and July, respectively, while device fundraising reached $325 million and $316 million in the same months.
Link:
Deals In Depth: June/July 2013
Tags: 316-million, 8-3-billion, a-licensed-rights, alliance-worth, biopharma-financing, fibro, finally-agreed, licensed-rights, qdss, regional-deal, same